NextGen China 2012

NextGen China 2012

NextGen China 2012 will bring together 120+ both top-level business and technical executives from global generic pharma and innovator pharma to discuss and showcase evolving generics landscape and solutions.

 7 Compelling Reasons for you to Attend NextGen China 2012
·Delving into key trends of generics regulatory, market and technology
·Hearing in-depth presentations from 25+ global speakers under CPhI resources
·Getting on-spot answers to your critical business and technical challenges from 10+ Q&A sessions
·Covering 3 hot topics: updated regulatory environment, ever-changing market and alliance, evolving technology and commercialization
·Networking with and 120+ decision makers from 30+ China’s pharmaceutical companies and 20+ MNCs from Asia Pacific, America, Europe, etc.
·Brainstorming with industry leaders in 2 workshop and 2 leaders’ think tank
·Benefiting from case studies from leading generic pharma

There are major shifts in the approach to the future opportunities for generic drugs:
·Global regulatory guidelines change.
·Blockbuster drug patents expire and IP infringements increase.
·Innovator Pharmas enter into generics market by M&A, strategic alliance and other partnerships.
·Innovative technology evolves in generics R&D and commercialization.
·Biosimilar is on emerging market.
These shifts have provided immens